Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Identifieur interne : 000729 ( PubMed/Curation ); précédent : 000728; suivant : 000730Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Auteurs : Devanshi J. Gohil [Inde] ; Sweta T. Kothari [Inde] ; Pramod S. Shinde [Inde] ; Anand S. Chintakrindi [Inde] ; Rhuta Meharunkar [Inde] ; Rajas V. Warke [Inde] ; Meena A. Kanyalkar [Inde] ; Abhay S. Chowdhary [Inde] ; Ranjana A. Deshmukh [Inde]Source :
- Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases [ 1567-7257 ] ; 2015.
Descripteurs français
- KwdFr :
- Amantadine (pharmacologie), Animaux, Antiviraux (pharmacologie), Cellules rénales canines Madin-Darby, Chiens, Grippe humaine (virologie), Humains, Inde, Mutation, Oséltamivir (analogues et dérivés), Oséltamivir (pharmacologie), Pandémies, Partie nasale du pharynx (virologie), Phylogénie, Protéines de la matrice virale (génétique), Résistance virale aux médicaments (), Sialidase (métabolisme), Sous-type H3N2 du virus de la grippe A (), Sous-type H3N2 du virus de la grippe A (génétique).
- MESH :
- analogues et dérivés : Oséltamivir.
- génétique : Protéines de la matrice virale, Sous-type H3N2 du virus de la grippe A.
- métabolisme : Sialidase.
- pharmacologie : Amantadine, Antiviraux, Oséltamivir.
- virologie : Grippe humaine, Partie nasale du pharynx.
- Animaux, Cellules rénales canines Madin-Darby, Chiens, Humains, Inde, Mutation, Pandémies, Phylogénie, Résistance virale aux médicaments, Sous-type H3N2 du virus de la grippe A.
English descriptors
- KwdEn :
- Amantadine (pharmacology), Animals, Antiviral Agents (pharmacology), Dogs, Drug Resistance, Viral (drug effects), Humans, India, Influenza A Virus, H3N2 Subtype (drug effects), Influenza A Virus, H3N2 Subtype (genetics), Influenza, Human (virology), Madin Darby Canine Kidney Cells, Mutation, Nasopharynx (virology), Neuraminidase (metabolism), Oseltamivir (analogs & derivatives), Oseltamivir (pharmacology), Pandemics, Phylogeny, Viral Matrix Proteins (genetics).
- MESH :
- chemical , analogs & derivatives : Oseltamivir.
- chemical , genetics : Viral Matrix Proteins.
- chemical , metabolism : Neuraminidase.
- chemical , pharmacology : Amantadine, Antiviral Agents, Oseltamivir.
- drug effects : Drug Resistance, Viral, Influenza A Virus, H3N2 Subtype.
- genetics : Influenza A Virus, H3N2 Subtype.
- virology : Influenza, Human, Nasopharynx.
- Animals, Dogs, Humans, India, Madin Darby Canine Kidney Cells, Mutation, Pandemics, Phylogeny.
Abstract
From its first instance in 1977, resistance to amantadine, a matrix (M2) inhibitor has been increasing among influenza A/H3N2, thus propelling the use of oseltamivir, a neuraminidase (NA) inhibitor as a next line drug. Information on drug susceptibility to amantadine and neuraminidase inhibitors for influenza A/H3N2 viruses in India is limited with no published data from Mumbai. This study aimed at examining the sensitivity to M2 and NA inhibitors of influenza A/H3N2 strains isolated from 2009 to 2011 in Mumbai.
DOI: 10.1016/j.meegid.2014.11.005
PubMed: 25461259
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000729
Links to Exploration step
pubmed:25461259Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.</title><author><name sortKey="Gohil, Devanshi J" sort="Gohil, Devanshi J" uniqKey="Gohil D" first="Devanshi J" last="Gohil">Devanshi J. Gohil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India. Electronic address: devanshi.gohil@gmail.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Kothari, Sweta T" sort="Kothari, Sweta T" uniqKey="Kothari S" first="Sweta T" last="Kothari">Sweta T. Kothari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Shinde, Pramod S" sort="Shinde, Pramod S" uniqKey="Shinde P" first="Pramod S" last="Shinde">Pramod S. Shinde</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bioinformatics, Guru Nanak Khalsa College, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Bioinformatics, Guru Nanak Khalsa College, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Chintakrindi, Anand S" sort="Chintakrindi, Anand S" uniqKey="Chintakrindi A" first="Anand S" last="Chintakrindi">Anand S. Chintakrindi</name><affiliation wicri:level="1"><nlm:affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Meharunkar, Rhuta" sort="Meharunkar, Rhuta" uniqKey="Meharunkar R" first="Rhuta" last="Meharunkar">Rhuta Meharunkar</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Warke, Rajas V" sort="Warke, Rajas V" uniqKey="Warke R" first="Rajas V" last="Warke">Rajas V. Warke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India; Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India; Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Kanyalkar, Meena A" sort="Kanyalkar, Meena A" uniqKey="Kanyalkar M" first="Meena A" last="Kanyalkar">Meena A. Kanyalkar</name><affiliation wicri:level="1"><nlm:affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Chowdhary, Abhay S" sort="Chowdhary, Abhay S" uniqKey="Chowdhary A" first="Abhay S" last="Chowdhary">Abhay S. Chowdhary</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Deshmukh, Ranjana A" sort="Deshmukh, Ranjana A" uniqKey="Deshmukh R" first="Ranjana A" last="Deshmukh">Ranjana A. Deshmukh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25461259</idno><idno type="pmid">25461259</idno><idno type="doi">10.1016/j.meegid.2014.11.005</idno><idno type="wicri:Area/PubMed/Corpus">000729</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000729</idno><idno type="wicri:Area/PubMed/Curation">000729</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000729</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.</title><author><name sortKey="Gohil, Devanshi J" sort="Gohil, Devanshi J" uniqKey="Gohil D" first="Devanshi J" last="Gohil">Devanshi J. Gohil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India. Electronic address: devanshi.gohil@gmail.com.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Kothari, Sweta T" sort="Kothari, Sweta T" uniqKey="Kothari S" first="Sweta T" last="Kothari">Sweta T. Kothari</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Shinde, Pramod S" sort="Shinde, Pramod S" uniqKey="Shinde P" first="Pramod S" last="Shinde">Pramod S. Shinde</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bioinformatics, Guru Nanak Khalsa College, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Bioinformatics, Guru Nanak Khalsa College, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Chintakrindi, Anand S" sort="Chintakrindi, Anand S" uniqKey="Chintakrindi A" first="Anand S" last="Chintakrindi">Anand S. Chintakrindi</name><affiliation wicri:level="1"><nlm:affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Meharunkar, Rhuta" sort="Meharunkar, Rhuta" uniqKey="Meharunkar R" first="Rhuta" last="Meharunkar">Rhuta Meharunkar</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Warke, Rajas V" sort="Warke, Rajas V" uniqKey="Warke R" first="Rajas V" last="Warke">Rajas V. Warke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India; Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India; Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Kanyalkar, Meena A" sort="Kanyalkar, Meena A" uniqKey="Kanyalkar M" first="Meena A" last="Kanyalkar">Meena A. Kanyalkar</name><affiliation wicri:level="1"><nlm:affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Chowdhary, Abhay S" sort="Chowdhary, Abhay S" uniqKey="Chowdhary A" first="Abhay S" last="Chowdhary">Abhay S. Chowdhary</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author><author><name sortKey="Deshmukh, Ranjana A" sort="Deshmukh, Ranjana A" uniqKey="Deshmukh R" first="Ranjana A" last="Deshmukh">Ranjana A. Deshmukh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra</wicri:regionArea></affiliation></author></analytic><series><title level="j">Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</title><idno type="eISSN">1567-7257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine (pharmacology)</term><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Dogs</term><term>Drug Resistance, Viral (drug effects)</term><term>Humans</term><term>India</term><term>Influenza A Virus, H3N2 Subtype (drug effects)</term><term>Influenza A Virus, H3N2 Subtype (genetics)</term><term>Influenza, Human (virology)</term><term>Madin Darby Canine Kidney Cells</term><term>Mutation</term><term>Nasopharynx (virology)</term><term>Neuraminidase (metabolism)</term><term>Oseltamivir (analogs & derivatives)</term><term>Oseltamivir (pharmacology)</term><term>Pandemics</term><term>Phylogeny</term><term>Viral Matrix Proteins (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Amantadine (pharmacologie)</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Cellules rénales canines Madin-Darby</term><term>Chiens</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Inde</term><term>Mutation</term><term>Oséltamivir (analogues et dérivés)</term><term>Oséltamivir (pharmacologie)</term><term>Pandémies</term><term>Partie nasale du pharynx (virologie)</term><term>Phylogénie</term><term>Protéines de la matrice virale (génétique)</term><term>Résistance virale aux médicaments ()</term><term>Sialidase (métabolisme)</term><term>Sous-type H3N2 du virus de la grippe A ()</term><term>Sous-type H3N2 du virus de la grippe A (génétique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Viral Matrix Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amantadine</term><term>Antiviral Agents</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Drug Resistance, Viral</term><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H3N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines de la matrice virale</term><term>Sous-type H3N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amantadine</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term><term>Partie nasale du pharynx</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term><term>Nasopharynx</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Dogs</term><term>Humans</term><term>India</term><term>Madin Darby Canine Kidney Cells</term><term>Mutation</term><term>Pandemics</term><term>Phylogeny</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules rénales canines Madin-Darby</term><term>Chiens</term><term>Humains</term><term>Inde</term><term>Mutation</term><term>Pandémies</term><term>Phylogénie</term><term>Résistance virale aux médicaments</term><term>Sous-type H3N2 du virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">From its first instance in 1977, resistance to amantadine, a matrix (M2) inhibitor has been increasing among influenza A/H3N2, thus propelling the use of oseltamivir, a neuraminidase (NA) inhibitor as a next line drug. Information on drug susceptibility to amantadine and neuraminidase inhibitors for influenza A/H3N2 viruses in India is limited with no published data from Mumbai. This study aimed at examining the sensitivity to M2 and NA inhibitors of influenza A/H3N2 strains isolated from 2009 to 2011 in Mumbai.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25461259</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1567-7257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2015</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases</Title><ISOAbbreviation>Infect. Genet. Evol.</ISOAbbreviation></Journal><ArticleTitle>Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.</ArticleTitle><Pagination><MedlinePgn>75-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.meegid.2014.11.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-1348(14)00408-0</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">From its first instance in 1977, resistance to amantadine, a matrix (M2) inhibitor has been increasing among influenza A/H3N2, thus propelling the use of oseltamivir, a neuraminidase (NA) inhibitor as a next line drug. Information on drug susceptibility to amantadine and neuraminidase inhibitors for influenza A/H3N2 viruses in India is limited with no published data from Mumbai. This study aimed at examining the sensitivity to M2 and NA inhibitors of influenza A/H3N2 strains isolated from 2009 to 2011 in Mumbai.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Nasopharyngeal swabs positive for influenza A/H3N2 virus were inoculated on Madin-Darby canine kidney (MDCK) cell line for virus isolation. Molecular analysis of NA and M2 genes was used to detect known mutations contributing to resistance. Resistance to neuraminidase was assayed using a commercially available chemiluminescence based NA-Star assay kit.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Genotypically, all isolates were observed to harbor mutations known to confer resistance to amantadine. However, no know mutations conferring resistance to NA inhibitors were detected. The mean IC50 value for oseltamivir was 0.25 nM. One strain with reduced susceptibility to the neuraminidase inhibitor (IC₅₀=4.08 nM) was isolated from a patient who had received oseltamivir treatment. Phylogenetic analysis postulate the emergence of amantadine resistance in Mumbai may be due to genetic reassortment with the strains circulating in Asia and North America.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Surveillance of drug susceptibility helped us to identify an isolate with reduced sensitivity to oseltamivir. Therefore, we infer that such surveillance would help in understanding possible trends underlying the emergence of resistant variants in humans.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gohil</LastName><ForeName>Devanshi J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India. Electronic address: devanshi.gohil@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothari</LastName><ForeName>Sweta T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinde</LastName><ForeName>Pramod S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Bioinformatics, Guru Nanak Khalsa College, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chintakrindi</LastName><ForeName>Anand S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meharunkar</LastName><ForeName>Rhuta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warke</LastName><ForeName>Rajas V</ForeName><Initials>RV</Initials><AffiliationInfo><Affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India; Molecular Biology and Virology, HiMedia Laboratories, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanyalkar</LastName><ForeName>Meena A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Principal K.M. Kundnani College of Pharmacy, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chowdhary</LastName><ForeName>Abhay S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deshmukh</LastName><ForeName>Ranjana A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Virology and Immunology, Haffkine Institute for Training, Research and Testing, Parel, Mumbai, Maharashtra, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Infect Genet Evol</MedlineTA><NlmUniqueID>101084138</NlmUniqueID><ISSNLinking>1567-1348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C488937">M2 protein, Influenza A virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014763">Viral Matrix Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>K6106LV5Q8</RegistryNumber><NameOfSubstance UI="C535162">oseltamivir carboxylate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="Y">Drug Resistance, Viral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061985" MajorTopicYN="N">Madin Darby Canine Kidney Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010802" MajorTopicYN="N">Phylogeny</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014763" MajorTopicYN="N">Viral Matrix Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amantadine</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Mumbai</Keyword><Keyword MajorTopicYN="N">Oseltamivir</Keyword><Keyword MajorTopicYN="N">Phylogenetic analysis</Keyword><Keyword MajorTopicYN="N">Surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>06</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>09</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25461259</ArticleId><ArticleId IdType="pii">S1567-1348(14)00408-0</ArticleId><ArticleId IdType="doi">10.1016/j.meegid.2014.11.005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000729 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000729 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25461259
|texte= Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25461259" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |